Alpha- Antitrypsin Deficiency Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Alpha-
Antitrypsin Deficiency – Pipeline Review, H1 2019” drug
pipelines has been added to ResearchAndMarkets.com’s
offering.

Alpha- Antitrypsin Deficiency – Pipeline Review, H1 2019, provides
comprehensive information on the therapeutics under development for
Alpha- Antitrypsin Deficiency (Genetic Disorders), complete with
analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.

The Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline guide
also reviews of key players involved in therapeutic development for
Alpha- Antitrypsin Deficiency and features dormant and discontinued
projects. The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in
Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical,
Discovery and Unknown stages are 1, 1, 4, 3, 12, 2 and 2 respectively.
Similarly, the Universities portfolio in Discovery stages comprises 1
molecules, respectively.

Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline guide helps
in identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Alpha- Antitrypsin Deficiency (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Alpha-
  Antitrypsin Deficiency (Genetic Disorders) by companies and
  universities/research institutes based on information derived from
  company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Alpha-
  Antitrypsin Deficiency (Genetic Disorders) therapeutics and enlists
  all their major and minor projects.
• The pipeline guide evaluates Alpha- Antitrypsin Deficiency (Genetic
  Disorders) therapeutics based on mechanism of action (MoA), drug
  target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Alpha- Antitrypsin Deficiency (Genetic Disorders)

Key Topics Covered:

1. Introduction
2. Report Coverage
3. Alpha- Antitrypsin Deficiency – Overview
4. Alpha- Antitrypsin Deficiency – Therapeutics Development
5. Pipeline Overview
6. Pipeline by Companies
7. Pipeline by Universities/Institutes
8. Products under Development by Companies
9. Products under Development by Universities/Institutes
10. Alpha- Antitrypsin Deficiency – Therapeutics Assessment
11. Assessment by Target
12. Assessment by Mechanism of Action
13. Assessment by Route of Administration
14. Assessment by Molecule Type
15. Alpha- Antitrypsin Deficiency – Companies Involved in Therapeutics
    Development

• Adverum Biotechnologies Inc
• Alnylam Pharmaceuticals Inc
• Applied Genetic Technologies Corp
• Arrowhead Pharmaceuticals Inc
• AstraZeneca Plc
• Editas Medicine Inc
• Grifols SA
• Inhibrx LP
• Intellia Therapeutics Inc
• International Stem Cell Corp
• Kamada Ltd
• Logicbio Therapeutics Inc
• OncBioMune Pharmaceuticals, Inc.
• PlantForm Corp
• Promethera Biosciences SA
• ProMetic Life Sciences Inc
• Santhera Pharmaceuticals Holding AG
• Vertex Pharmaceuticals Inc
• Z Factor Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/z3mtcu

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Respiratory
Drugs